Vitamin E in disease prevention - A critical appraisal of vitamin E supplementation trials;Die rolle von vitamin E in der prävention degenerativer erkrankungen - Eine kritische betrachtung von vitamin-E-supplementationsstudien

Aktuelle Ernahrungsmedizin

Volumn 34, Issue 3, 2009, Pages 131-140

  Frank, Jan ^a   Rimbach, G ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Disease prevention; Genotype; Human trials; Tocopherol; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; ASCORBIC ACID; CYTOCHROME P450 2B; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; HAPTOGLOBIN; ISOPROSTANE DERIVATIVE;

ALLELE; DEGENERATIVE DISEASE; DIABETIC PATIENT; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; GENOTYPE; HEALTH; HETEROZYGOTE; HUMAN; LIPID PEROXIDATION; METHODOLOGY; MORTALITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; POPULATION; PROPHYLAXIS; REFERENCE VALUE; REVIEW; SCREENING; STEREOISOMERISM; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 77149155298     PISSN: 03410501     EISSN: 14389916     Source Type: Journal    
DOI: 10.1055/s-0028-1090205     Document Type: Review

References (100)

1. Evans HM, Bishop KS. On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science 1922; 56: 650-651
2. Mason KE. The first two decades of vitamin E. Fed Proc 1977; 36: 1906-1910
3. Evans HM, Emerson OH, Emerson GA. The isolation from wheat germ oil of an alcohol, α-tocopherol, having the properties of vitamin E. J Biol Chem 1936; 113: 319-332
4. Kamal-Eldin A, Appelqvist LÅ. The Chemistry and Antioxidant Proper-ties of Tocopherols and Tocotrienols. Lipids 1996; 31: 671-701
5. Lampi AM, Kamal-Eldin A, Piironen V. Tocopherols and Tocotrienols from Oil and Cereal Grains. In: Shi J, Mazza G, Le Maguer M, eds. Functional Foods - Biochemical and Processing Aspects. Boca Raton: CRC Press, 2002: 1-38
6. Munne-Bosch S, Alegre L. The function of tocopherols and tocotrie-nols in plants. Critical Reviews in Plant Sciences 2002; 21: 31-57
7. Packer L, Obermüller-Jevic UC. Vitamin E: An Introduction. In: Packer L, Traber MG, Kraemer K, Frei B, eds. The Antioxidant Vitamins C and E. Champaign, IL, USA: AOCS Press, 2002: 133-151
8. Nationale Verzehrsstudie II: Ergebnisbericht, Teil 2. Karlsruhe: Max-Rubner-Institut, 2008 (URL: http://www.was-esse-ich.de/uploads/ media/NVSII-Ergebnisbericht-Teil2.pdf)
9. Deutsche Gesellschaft für Ernährung (DGE). Reference values for nu-trient intake. 1st ed. Frankfurt/Main: Umschau/Braus, 2000
10. Mensink GB, Beitz R. Food and nutrient intake in East and West Ger-many, 8 years after the reunification - The German Nutrition Survey 1998. Eur J Clin Nutr 2004; 58: 1000-1010
11. Maras JE, Bermudez OI, Qiao N et al. Intake of alpha-tocopherol is lim-ited among US adults. J Am Diet Assoc 2004; 104: 567-575
12. Food and Nutrition Board of the Institute of Medicine. Dietary Refer-ence Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000: 506
13. Olcott HS, Emerson OH. Antioxidants and the Autoxidation of Fats. IX. The Antioxidant Properties of the Tocopherols. J Am Chem Soc 1937; 59: 1008-1009
14. Dam H. Vitamin E as an in vivo antioxidant. Experientia 1952; 1: 195-213
15. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of alpha-tocopherol (vitamin E). FEBS Lett 2002; 519: 8-10
16. Rimbach G, Minihane AM, Majewicz J et al. Regulation of cell signal-ling by vitamin E. Proc Nutr Soc 2002; 61: 415-425
17. Packer L, Weber SU, Rimbach G. Molecular aspects of α-tocotrienol antioxidant action and cell signalling. J Nutr 2001; 131: 369S-373S
18. Barella L, Muller PY, Schlachter M et al. Identification of hepatic mo-lecular mechanisms of action of alpha-tocopherol using global gene expression profile analysis in rats. Biochim Biophys Acta 2004; 1689: 66-74
19. Muller PY, Netscher T, Frank J et al. Comparative quantification of pharmacodynamic parameters of chiral compounds (RRR- vs. all-rac-alpha tocopherol) by global gene expression profiling. J Plant Physiol 2005; 162: 811-817
20. Nier B, Weinberg PD, Rimbach G et al. Differential gene expression in skeletal muscle of rats with Vitamin E deficiency. IUBMB Life 2006; 58: 540-548
21. Rimbach G, Fischer A, Stoecklin E et al. Modulation of hepatic gene ex-pression by alpha-tocopherol in cultured cells and in vivo. Ann N Y Acad Sci 2004; 1031: 102-108
22. Rota C, Barella L, Minihane AM et al. Dietary alpha-tocopherol affects differential gene expression in rat testes. IUBMB Life 2004; 56: 277-280
23. Rota C, Rimbach G, Minihane AM et al. Dietary vitamin E modulates differential gene expression in the rat hippocampus: Potential impli-cations for its neuroprotective properties. Nutritional Neuroscience 2005; 8: 21-29
24. Gaedicke S, Zhang X, Schmelzer C et al. Vitamin E dependent micro-RNA regulation in rat liver. FEBS Lett 2008; 582: 3542-3546
25. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 1995; 61: 1-31
26. Ceriello A, Motz E. Is Oxidative Stress the Pathogenic Mechanism Un-derlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823
27. Keaney JF Jr, Larson MG, Vasan RS et al. Obesity and systemic oxida-tive stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23: 434-439
28. Rimm EB, Stampfer MJ, Ascherio A et al. Vitamin E consumption and the risk of coronary heart disease in men. The New England journal of medicine 1993; 328: 1450-1456
29. Stampfer MJ, Hennekens CH, Manson JE et al. Vitamin E consumption and the risk of coronary disease in women. The New England journal of medicine 1993; 328: 1444-1449
30. Gey KF, Puska P, Jordan P et al. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultur-al epidemiology. Am J Clin Nutr 1991; 53: 326S-334S
31. Riemersma RA, Wood DA, Macintyre CC et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lan-cet 1991; 337: 1-5
32. Jialal I, Devaraj S. Scientific evidence to support a vitamin e and heart disease health claim: research needs. J Nutr 2005; 135: 348-353
33. Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857
34. rd, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46
35. Bell SJ, Grochoski GT. How safe is vitamin E supplementation? Crit Rev Food Sci Nutr 2008; 48: 760-774
36. Hathcock JN, Azzi A, Blumberg J et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 2005; 81: 736-745
37. Block G, Jensen CD, Morrow JD et al. The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med 2008; 45: 377-384
38. nd, Oates JA, Linton MF et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007; 43: 1388-1393
39. Landes N, Pfluger P, Kluth D et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 2003; 65: 269-273
40. Cholerton S, Daly AK, Idle JR. The role of individual human cyto-chromes P450 in drug metabolism and clinical response. Trends in pharmacological sciences 1992; 13: 434-439
41. Mustacich DJ, Leonard SW, Devereaux MW et al. α-Tocopherol regula-tion of hepatic cytochrome P450s and ABC transporters in rats. Free Radic Biol Med 2006; 41: 1069-1078
42. Hundhausen C, Frank J, Rimbach G et al. Effect of Vitamin E on Cyto-chrome P450 mRNA Levels in Cultured Hepatocytes (HepG2) and in Rat Liver. Cancer Genomics & Proteomics 2006; 3: 183-190
43. Kluth D, Landes N, Pfluger P et al. Modulation of Cyp3a11 mRNA ex-pression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med 2005; 38: 507-514
44. Traber MG, Elsner A, Brigelius-Flohé R. Synthetic as compared with natural vitamin E is preferentially excreted as α-CEHC in human ur-ine: studies using deuterated a-tocopheryl acetates. FEBS Lett 1998; 437: 145-148
45. Jeanes YM, Hall WL, Ellard S et al. The absorption of vitamin E is influ-enced by the amount of fat in a meal and the food matrix. Br J Nutr 2004; 92: 575-579
46. Leonard SW, Good CK, Gugger ET et al. Vitamin E bioavailability from fortified breakfast cereal is greater than that from encapsulated sup-plements. Am J Clin Nutr 2004; 79: 86-92
47. Bruno RS, Leonard SW, Park SI et al. Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled al-pha-tocopheryl acetate. Am J Clin Nutr 2006; 83: 299-304
48. Frank J. Beyond vitamin E supplementation: an alternative strategy to improve vitamin E status. J Plant Physiol 2005; 162: 834-843
49. Frank J, Lee S, Leonard SW et al. Sex differences in the inhibition of gamma-tocopherol metabolism by a single dose of dietary sesame oil in healthy subjects. Am J Clin Nutr 2008; 87: 1723-1729
50. Hall WL, Jeanes YM, Lodge JK. Hyperlipidemic Subjects Have Reduced Uptake of Newly Absorbed Vitamin E into Their Plasma Lipoproteins, Erythrocytes, Platelets, and Lymphocytes, as Studied by Deuterium-Labeled {alpha}-Tocopherol Biokinetics. J Nutr 2005; 135: 58-63
51. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heteroge-neity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981; 256: 9077-9083
52. Singh PP, Singh M, Mastana SS. APOE distribution in world popula-tions with new data from India and the UK. Annals of human biology 2006; 33: 279-308
53. Eichner JE, Dunn ST, Perveen G et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155: 487-495
54. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999; 53: 1308-1311
55. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137-147
56. Humphries SE, Talmud PJ, Hawe E et al. Apolipoprotein E4 and coron-ary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001; 358: 115-119
57. Lahoz C, Schaefer EJ, Cupples LA et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Athero-sclerosis 2001; 154: 529-537
58. Talmud PJ. Gene-environment interaction and its impact on coronary heart disease risk. Nutr Metab Cardiovasc Dis 2007; 17: 148-152
59. Talmud PJ, Stephens JW, Hawe E et al. The significant increase in car-diovascular disease risk in APOEe4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Annals of human genetics 2005; 69: 613-622
60. Mabile L, Lefebvre C, Lavigne J et al. Secreted apolipoprotein E reduces macrophage-mediated LDL oxidation in an isoform-dependent way. J Cell Biochem 2003; 90: 766-776
61. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant ac-tivity and effects on cytotoxicity by oxidative insults and beta-amy-loid peptides. Nat Genet 1996; 14: 55-61
62. Dietrich M, Hua Y, Block G et al. Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids 2005; 40: 329-334
63. Tsuda M, Sanada M, Nakagawa H et al. Phenotype of apolipoprotein E influences the lipid metabolic response of postmenopausal women to hormone replacement therapy. Maturitas 2001; 38: 297-304
64. Lodge JK, Hall WL, Jeanes YM et al. Physiological factors influencing vitamin E biokinetics. Ann N Y Acad Sci 2004; 1031: 60-73
65. Mas E, Dupuy AM, Artero S et al. Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease. Dement Geriatr Cogn Dis-ord 2006; 21: 198-204
66. Jofre-Monseny L, Huebbe P, Stange I et al. Influence of apolipoprotein E genotype and dietary alpha-tocopherol on redox status and C-re-active protein levels in apolipoprotein E3 and E4 targeted replace-ment mice. Br J Nutr 2008; 100: 44-53
67. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Advances in human genetics 1982; 12: 189-261, 453-454
68. Miller YI, Altamentova SM, Shaklai N. Oxidation of low-density lipo-protein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry 1997; 36: 12189-12198
69. Melamed-Frank M, Lache O, Enav BI et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001; 98: 3693-3698
70. Carter K, Worwood M. Haptoglobin: a review of the major allele fre-quencies worldwide and their association with diseases. Interna-tional journal of laboratory hematology 2007; 29: 92-110
71. Asleh R, Marsh S, Shilkrut M et al. Genetically determined heteroge-neity in hemoglobin scavenging and susceptibility to diabetic cardi-ovascular disease. Circ Res 2003; 92: 1193-1200
72. Bamm VV, Tsemakhovich VA, Shaklai M et al. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 2004; 43: 3899-3906
73. Tseng CF, Lin CC, Huang HY et al. Antioxidant role of human haptoglo-bin. Proteomics 2004; 4: 2221-2228
74. Brouwers A, Langlois M, Delanghe J et al. Oxidized low-density lipo-protein, iron stores, and haptoglobin polymorphism. Atherosclerosis 2004; 176: 189-195
75. Bernard D, Christophe A, Delanghe J et al. The effect of supplementa-tion with an antioxidant preparation on LDL-oxidation is deter-mined by haptoglobin polymorphism. Redox Rep 2003; 8: 41-46
76. Levy AP, Hochberg I, Jablonski K et al. Haptoglobin phenotype is an in-dependent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. Journal of the American College of Cardiology 2002; 40: 1984-1990
77. Burbea Z, Nakhoul F, Zoabi R et al. Haptoglobin phenotype as a predic-tive factor of mortality in diabetic haemodialysis patients. Annals of clinical biochemistry 2004; 41: 469-473
78. Levy AP, Friedenberg P, Lotan R et al. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by hapto-globin type in postmenopausal women. Diabetes Care 2004; 27: 925-930
79. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary athero-sclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-2440
80. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and car-diovascular events in high-risk patients. The Heart Outcomes Pre-vention Evaluation Study Investigators. The New England journal of medicine 2000; 342: 154-160
81. Levy AP, Gerstein HC, Miller-Lotan R et al. The effect of vitamin E sup-plementation on cardiovascular risk in diabetic individuals with dif-ferent haptoglobin phenotypes. Diabetes Care 2004; 27: 2767
82. Milman U, Blum S, Shapira C et al. Vitamin E Supplementation Reduc-es Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Geno-type - A Prospective Double-Blinded Clinical Trial. Arterioscler Thromb Vasc Biol 2008; 28: 341-347
83. Döring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life 2004; 56: 615-620
84. Borel P, Moussa M, Reboul E et al. Human plasma levels of vitamin E and carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism. J Nutr 2007; 137: 2653-2659
85. Sundl I, Guardiola M, Khoschsorur G et al. Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene - 1131T >C variant and associations with plasma lipids and lipid perox-idation. J Lipid Res 2007; 48: 2506-2513
86. Testa R, Bonfigli AR, Sirolla C et al. Effect of 4G/5G PAI-1 polymorph-ism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients. Diabetes, nutrition & metabolism 2004; 17: 217-221
87. Hoppe PP, Krennrich G. Bioavailability and potency of natural-source and all-racemic α-tocopherol in the human: a dispute. Eur J Nutr 2000; 39: 183-193
88. O'Byrne D, Grundy S, Packer L et al. Studies of LDL oxidation following α-, γ-, or δ-tocotrienyl acetate supplementation of hypercholestero-lemic humans. Free Radic Biol Med 2000; 29: 834-845
89. Hensley K, Benaksas EJ, Bolli R et al. New Perspectives on Vitamin E: γ-Tocopherol and Carboxyethylhydroxychroman Metabolites in Biolo-gy and Medicine. Free Radic Biol Med 2004; 36: 1-15
90. Cooney RV, Custer LJ, Okinaka L et al. Effects of dietary sesame seeds on plasma tocopherol levels. Nutr Cancer 2001; 39: 66-71
91. The alpha-Tocopherol, beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The New England journal of medicine 1994; 330: 1029-1035
92. Salonen JT, Nyyssonen K, Salonen R et al. Antioxidant Supplementa-tion in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. Journal of internal medicine 2000; 248: 377-386
93. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the pre-vention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008; 300: 2123-2133
94. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovas-cular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95
95. Hodis HN, Mack WJ, LaBree L et al. Alpha-tocopherol supplementa-tion in healthy individuals reduces low-density lipoprotein oxida-tion but not atherosclerosis: the Vitamin E Atherosclerosis Preven-tion Study (VEAPS). Circulation 2002; 106: 1453-1459
96. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary preven-tion of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56-65
97. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786
98. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocar-dico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Pre-venzione trial. Lancet 1999; 354: 447-455
99. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with anti-oxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218
100. Cook NR, Albert CM, Gaziano JM et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxi-dant Cardiovascular Study. Archives of internal medicine 2007; 167: 1610-1618